Dogwood Therapeutics Q2 net loss rises to $11.5 million on impairment charge
Dogwood Therapeutics reported a second-quarter 2026 net loss attributable to common stockholders of $11.5 million, or $0.34 per share, compared with $3.8 million, or $1.99 per share, a year earlier. The loss increase reflects a $9.2 million non-cash IPR&D impairment, and the company reported no revenue in either period. The company said the impairment does not affect its cash runway, which it stated extends through the Phase 2b Halneuron readout in the fourth quarter of 2026.
Key points
- Q2 2026 net loss of $11.5 million versus $3.8 million in Q2 2025; no revenue in either period
- IPR&D impairment of $9.2 million in Q2 2026, partly offset by a $2.5 million deferred tax benefit, for a net impairment of $6.7 million
- R&D expenses rose to $3.2 million from $2.6 million; G&A rose to $1.6 million from $1.3 million
- Cash of $9.6 million at June 30, 2026, which the company says funds operations through the Phase 2b readout in Q4 2026
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.